Synthetic Biology will reinvent Nature and ourselves...
Synthetic biology is entering a new era thanks to the emergence of disruptive technologies that will impact many fields including bioproduction, agriculture, data storage and human gene and cell therapy.
Our investment portfolio
Omne Possibile has assembled an innovative team, together with leading academic partners, to adapt the chemical formats conveying genetic information to the processes desired by the industry. Developing such chemical formats – known as XNA – combines diverse disciplines including chemical synthesis, genetics, directed evolution of enzymes and genomes, automated design of molecules and bioproduction pathways.